
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. demonstrated a modest year-over-year growth in EsoGuard test volume, achieving 2,841 tests in Q3 2025, marking a 2% increase from the previous year and showing consistent quarterly growth. The company's proactive expansion of coverage for EsoGuard, including efforts with Medicare and private payers, positions it for substantial revenue growth as it enhances accessibility for a larger patient base. The recent positive developments from the MolDX CAC meeting and increased engagement with Medicare customers suggest a favorable outlook, highlighting the potential for significant revenue upside while balancing associated risks.
Bears say
Lucid Diagnostics Inc experienced a disappointing financial performance in 3Q25, as the company missed consensus revenue estimates while reporting a pro forma net loss of $10.3 million, reflecting ongoing financial challenges. The decline in EsoGuard test processing volumes, which fell from 3,034 in Q1 to 2,756 in Q2, indicates potential hurdles in market adoption and effectiveness of marketing strategies. Additionally, significant risks persist regarding reimbursement from insurers, competition from alternative tests, and overall liquidity concerns, all of which contribute to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares